Summary & Overview
CPT 81511: Multianalyte Serum Screening with Algorithmic Risk Score
CPT code 81511 designates a laboratory service that combines technical testing of four analytes — AFP, uE3, hCG, and DIA — with an algorithmic analysis incorporating patient data to produce a patient risk score. This type of multianalyte serum screening is clinically significant for stratifying risk in prenatal assessment and similar applications where biomarker panels inform clinical decision-making. Nationally, utilization of algorithm-based laboratory reporting has implications for coverage policy, clinical pathways, and laboratory workflows.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the code, typical sites of service, common modifiers, and contextual guidance on where this service fits in laboratory and prenatal screening pathways. The publication summarizes payer coverage patterns, coding and billing considerations, and operational implications for laboratories that perform multianalyte testing with algorithmic risk reporting. Data not available in the input is noted where applicable, and the content focuses on national-level relevance for clinicians, laboratory administrators, and billing professionals.
Billing Code Overview
CPT code 81511 describes a laboratory service in which a lab analyst performs technical testing for four analytes — alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and DIA — and applies an algorithmic analysis combining those test results with patient data to generate and report a patient risk score. This service is a combined analytic and reporting procedure that delivers a calculated risk assessment based on multiple serum markers and clinical inputs.
-
Service type: Multianalyte serum screening with algorithmic risk assessment
-
Typical site of service: Clinical laboratory or diagnostic laboratory setting where serum analyte testing and algorithmic reporting are performed
Clinical & Coding Specifications
Clinical Context
A pregnant patient presents for second-trimester aneuploidy screening between 15 and 22 weeks gestation. Maternal serum is collected in an outpatient lab or obstetrics clinic for measurement of four analytes: alpha-fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (hCG), and dimeric inhibin A (DIA). The laboratory performs the technical assays and then combines the measured values with patient-specific data (maternal age, gestational age, weight, race/ethnicity, prior obstetric history) and applies a validated algorithm to generate a patient-specific risk score for fetal chromosomal abnormalities (for example, trisomy 21 and trisomy 18) and neural tube defects. Typical site of service is an independent clinical laboratory or hospital outpatient laboratory; specimen collection often occurs in an outpatient obstetrics clinic, community phlebotomy center, or ambulatory surgery center when bundled with other prenatal services. Clinical workflow: order placed by an obstetrician, maternal-fetal medicine specialist, or primary care clinician; specimen collected and shipped to the reference lab; lab performs assays and algorithmic analysis under the technical component; result report transmitted to ordering clinician who interprets the risk score and discusses next steps with the patient (diagnostic testing or additional imaging).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/standard - no modifier | Use when no special reporting modifier applies to the claim |